Roivant’s Ambitious $1.5 Billion Share Repurchase Plan – Buyback Wednesdays

Roivant Sciences Ltd. (ROIV): $10.9

Market Cap: $8.78B

EV: $2.61B

Roivant Sciences (ROIV) stands out in the pharmaceutical industry for two key reasons: its unique business approach and the fascinating background of its founder, Vivek Ramaswamy. Ramaswamy, an American entrepreneur and politician, founded Roivant Sciences in 2014. He gained attention in February 2023 when he announced his candidacy for the Republican Party nomination in the 2024 United States presidential election, though he later suspended his campaign in January 2024 after finishing fourth in Iowa’s caucuses.

A Harvard graduate in biology with a law degree from Yale Law School, Ramaswamy initially interned for hedge fund Amaranth Advisors and Goldman Sachs. He later co-managed the biotech portfolio at hedge fund QVT Financial, where he became an investment partner. Additionally, he co-founded investment firm Strive Asset Management. Interestingly, Ramaswamy served as Chairman for two pharmaceutical companies, OnCore Biopharma and Arbutus Biopharma, before founding one himself!

Only plus or premium subscribers can access this post. Subscribe today.